Biomet

As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.04 earnings per share for the current fiscal year.

Finally, TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b” rating in a report on Tuesday, May 2nd.

First Hawaiian Bank’s holdings in Zimmer Biomet were worth $788,000 as of its most recent SEC filing.

Morgan Stanley reissued an “equal weight” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, August 2nd.

Price T Rowe Associates Inc. MD increased its position in Zimmer Biomet by 13.5% during the 2nd quarter.

Ronald Blue Trust Inc. bought a new stake in Zimmer Biomet in the second quarter worth about $37,000.

Vanguard Personalized Indexing Management LLC grew its holdings in Zimmer Biomet by 14.6% in the 2nd quarter.

Zimmer Biomet's manufacturing plant is about a mile from another former key employer in Bridgend, the Ford engine plant.

Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $137.

Clear Street Markets LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter worth about $27,000.

Quent Capital LLC boosted its stake in Zimmer Biomet by 21.6% in the fourth quarter.

Crewe Advisors LLC grew its holdings in shares of Zimmer Biomet by 65.0% in the third quarter.

Finally, BTIG Research reaffirmed a “buy” rating and set a $139.00 price target on shares of Zimmer Biomet in a research note on Tuesday, August 4th.

The major players in the global spinal implants market include Stryker Corp., Zimmer Biomet Holdings, Inc., Medtronic PLC, Johnson & Johnson Services, Inc. and Smith & Nephew PLC.

Zimmer Biomet had a net margin of 4.84% and a return on equity of 13.29%.

Zimmer Biomet had a return on equity of 13.29% and a net margin of 4.84%.

As a group, equities research analysts anticipate that Zimmer Biomet will post 7.81 earnings per share for the current year.

BlackRock Inc. raised its holdings in shares of Zimmer Biomet by 3.2% during the first quarter.

Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 target price on the stock in a research note on Monday, April 8th.

Finally, upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday.